AMENDMENTS TO THE CLAIMS

1. (Original): An improved vaccine composition that includes an antigen, wherein the improvement comprises ribavirin.

2. (Original): The improved vaccine composition of Claim 1, wherein said antigen is a viral antigen.

3. (Original): The improved vaccine composition of Claim 1, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

4. (Original): The improved vaccine composition of Claim 1, wherein said antigen is obtained from hepatitis C virus.

5. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is at least 0.25mg.

6. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 100mg.

7. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 25mg.

8. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 1mg.

9. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.

10. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.

11. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.

12. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

13. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

14. (Original): A method of making the improved vaccine composition of Claim 1 comprising:

providing an antigen;

providing ribavirin; and

combining said antigen and said ribavirin so as to make said improved vaccine composition.

15. (Original): The method of Claim 14, wherein said antigen is a viral antigen.

16. (Original): The method of Claim 14, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

17. (Original): The method of Claim 14, wherein said antigen is obtained from hepatitis C virus.

18. (Original): The method of Claim 14, wherein the amount of ribavirin is at least 0.25mg.

19. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 100mg.

20. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 25mg.

21. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 1mg.

22. (Original): The method of Claim 14, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.

23. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.

24. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.

25. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

26. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

27. (Original): A method of enhancing an immune response to an antigen comprising:

providing a subject the improved vaccine composition of Claim 1.

28. (Original): The method of Claim 25, wherein said antigen is a viral antigen.

29. (Original): The method of Claim 25, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

30. (Original): The method of Claim 26, wherein said antigen is obtained from hepatitis C virus.

31. (Original): An improved method of enhancing an immune response to an antigen that includes providing a subject an antigen, wherein the improvement comprises providing ribavirin.

32. (Original): The improved method of Claim 31, wherein said antigen and said ribavirin are provided together.

33. (Original): The improved method of Claim 31, wherein said antigen and ribavirin are provided separately.

34. (New): A method of enhancing a production of antibodies specific for a viral antigen comprising:

identifying a subject in need of an enhanced production of antibodies specific for a viral antigen; and

providing to said subject an immunogenic composition comprising a viral antigen and ribavirin.

35. (New): The method of Claim 34, wherein the amount of ribavirin is at least 0.25mg.

36. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 100mg.

37. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 25mg.

38. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 1mg.

39. (New): The method of Claim 34, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.

40. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.

41. (New): The method of Claim 34, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.

42. (New): The method of Claim 34, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

43. (New): The method of Claim 34, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

44. (New): The method of Claim 34, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

45. (New): The method of Claim 34, wherein said antigen is obtained from hepatitis C virus.

46. (New): A method of enhancing a production of antibodies specific for a viral antigen comprising:

providing an immunogenic composition comprising a viral antigen and ribavirin to a subject; and

measuring the production of antibodies specific for said viral antigen.

47. (New): The method of Claim 46, wherein said measuring comprises measuring a reduction of viral load.

48. (New): A method of treating or preventing a disease comprising:

identifying a subject in need of treatment or prevention of a disease; and

co-administering to said subject a composition comprising an antigen and a composition comprising ribavirin.

49. (New): The method of Claim 48, wherein the antigen and ribavirin are administered in a single composition.

50. (New): The method of Claim 48, wherein the disease is selected from the group consisting of the disease caused by hepatitis A virus, the disease caused by hepatitis B virus, and the disease caused by hepatitis C virus.